Document is current

Article History

Accepted: 16 September 2021

First Online: 1 November 2021

Declarations

:

: This work was supported by the NCI under award number K08CA238711 (AAC), the V Foundation for Cancer Research V Scholar Award (AAC), the Cancer Research Foundation Young Investigator Award (AAC), and the Washington University Alvin J. Siteman Cancer Research Fund (AAC). The funders had no role in the preparation of the manuscript.

: KC, PSC, and RJR have patent filings related to cancer biomarkers. JPZ has patent filings related to cancer biomarkers, research support from Naveris, served as medical director to Summit Biolabs, and has ownership interests in Droplet Biosciences. BP has research support from BMS; speaker honoraria from BioAscend, OncLive, and MJH Life Sciences; and has served as an advisor/consultant to AstraZeneca, Guardant Health, and Guidepoint. AAC has patent filings related to cancer biomarkers, and has served as a consultant/advisor to Roche, Tempus, Geneoscopy, Daiichi Sankyo, AstraZeneca, NuProbe, Fenix Group International, and Guidepoint; AAC has stock options in Geneoscopy, research support from Roche, and ownership interests in Droplet Biosciences. MDS, PKH, MAR, and AAD declare that they have no conflicts of interest that might be relevant to the contents of this review.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: KC, MDS, AAD, BP, and AAC conceived of the study. KC, MDS, PSC, RJR, PKH, AAD, BP, and AAC performed the literature search, data collection, data curation, data interpretation, and writing of the manuscript. All authors edited the manuscript and commented on the manuscript at all stages.